ForteBio Appoints Plexxikon CEO Peter Hirth to its Board

Jun 15, 2006

MENLO PARK, Calif. – June 15, 2006 – ForteBio, Inc., developer of label-free systems for real-time detection and analysis of molecular interactions, today announced the election of K. Peter Hirth, Ph.D., to its Board of Directors. Dr. Hirth is Co-Founder and Chief Executive Officer of Plexxikon, a biotechnology leader in the discovery and development of novel small molecule pharmaceuticals to treat human disease.

“I am very pleased to welcome Peter Hirth to our board, as he brings extensive experience in drug development in the markets we serve, namely the biotechnology and pharmaceutical industries,” stated Winnie H. Wan, Ph.D., President and Chief Executive Officer of ForteBio. “Peter’s participation as a board member will help ForteBio to identify new trends in drug development and better define our customers’ needs, particularly in the small molecule drug market.”

Dr. Hirth co-founded Plexxikon in December 2000, and has 20 years of biotechnology and pharmaceutical discovery and development experience. Previously, he was president of Sugen, Inc. until the sale of the company to Pharmacia Corporation in 1999. At Sugen, he helped build the company from its inception and advanced several kinase inhibitors through clinical trials for the treatment of oncology. Prior to Sugen, Dr. Hirth was a vice president in research with Boehringer Mannheim where, among other responsibilities, he successfully led the company's erythropoietin program. Previously, he also was a research scientist with the Max Planck Institute, following the completion of his post doctoral work at the University of California, San Diego. Dr. Hirth received his Ph.D. in molecular genetics from Heidelberg University, Germany.

In addition to Dr. Hirth, other members of the ForteBio board include Dr. Wan; Brian Atwood, Co-Founder of Versant Ventures; Yue-Teh Jang, Ph.D., General Partner of the Vertical Group; Deborah Neff, President and Chief Executive Officer of Predicant Bioscience, Inc.; Craig Taylor, Partner at Alloy Ventures; and James Woody, M.D., Ph.D., General Partner at Latterell Venture Partners.

About ForteBio, Inc.
ForteBio is a venture-capital funded life science company providing analytical systems to accelerate the development of therapeutics. These systems enable real-time analysis of biomolecular interactions providing information on affinity, kinetics and concentration. Most importantly, ForteBio’s analytical capabilities enable better and faster characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance and cost. The company is located in Menlo Park, California. For more information, please visit www.fortebio.com.

Contact Information :
Winnie H. Wan, Ph.D.
President & Chief Executive Officer
650-322-1360 ext. 111
wwan@fortebio.com